MX2010007083A - Combinacion anti-retroviral. - Google Patents

Combinacion anti-retroviral.

Info

Publication number
MX2010007083A
MX2010007083A MX2010007083A MX2010007083A MX2010007083A MX 2010007083 A MX2010007083 A MX 2010007083A MX 2010007083 A MX2010007083 A MX 2010007083A MX 2010007083 A MX2010007083 A MX 2010007083A MX 2010007083 A MX2010007083 A MX 2010007083A
Authority
MX
Mexico
Prior art keywords
ester
retroviral combination
pharmaceutically acceptable
acceptable salt
retroviral
Prior art date
Application number
MX2010007083A
Other languages
English (en)
Spanish (es)
Inventor
Amar Lulla
Geena Malhotra
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54289250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010007083(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of MX2010007083A publication Critical patent/MX2010007083A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/03—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor characterised by the shape of the extruded material at extrusion
    • B29C48/04—Particle-shaped
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/25—Component parts, details or accessories; Auxiliary operations
    • B29C48/78—Thermal treatment of the extrusion moulding material or of preformed parts or layers, e.g. by heating or cooling
    • B29C48/80—Thermal treatment of the extrusion moulding material or of preformed parts or layers, e.g. by heating or cooling at the plasticising zone, e.g. by heating cylinders
    • B29C48/83—Heating or cooling the cylinders
    • B29C48/832—Heating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
MX2010007083A 2007-12-24 2008-12-24 Combinacion anti-retroviral. MX2010007083A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2538MU2007 2007-12-24
PCT/GB2008/004291 WO2009081174A2 (en) 2007-12-24 2008-12-24 Anti - retroviral combination

Publications (1)

Publication Number Publication Date
MX2010007083A true MX2010007083A (es) 2010-10-20

Family

ID=54289250

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010007083A MX2010007083A (es) 2007-12-24 2008-12-24 Combinacion anti-retroviral.

Country Status (20)

Country Link
US (1) US9339470B2 (ar)
EP (2) EP2242482B1 (ar)
JP (2) JP2011507940A (ar)
CN (2) CN103638032A (ar)
AP (2) AP2013007064A0 (ar)
AT (1) ATE555778T1 (ar)
AU (1) AU2008339633A1 (ar)
BR (1) BRPI0819534A2 (ar)
CA (1) CA2710605C (ar)
DK (1) DK2242482T3 (ar)
ES (2) ES2674730T3 (ar)
GT (1) GT200800303A (ar)
HK (1) HK1149905A1 (ar)
JO (2) JO2814B1 (ar)
MX (1) MX2010007083A (ar)
PA (1) PA8809601A1 (ar)
PE (2) PE20091530A1 (ar)
RU (2) RU2531089C2 (ar)
WO (1) WO2009081174A2 (ar)
ZA (1) ZA201004505B (ar)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200800303A (es) 2007-12-24 2009-09-18 Combinacion anti-retroviral
US8921415B2 (en) 2009-01-29 2014-12-30 Mapi Pharma Ltd. Polymorphs of darunavir
WO2011092687A1 (en) 2010-01-28 2011-08-04 Mapi Pharma Hk Limited Process for the preparation of darunavir and darunavir intermediates
CA2822639A1 (en) * 2010-12-22 2012-06-28 The Feinstein Institute For Medical Research Methods for treating systemic lupus erythematosus using hiv protease inhibitors
HUE035241T2 (en) 2011-07-07 2018-05-02 Janssen Sciences Ireland Uc Darunavir combination products
BR112014000195A2 (pt) * 2011-07-07 2017-02-21 Janssen R&D Ireland formulações de darunavir
WO2013164559A1 (en) * 2012-05-03 2013-11-07 Cipla Limited Antiretroviral composition
RU2505286C1 (ru) * 2012-12-29 2014-01-27 Открытое Акционерное Общество "Фармасинтез" Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
MX2016002560A (es) 2013-08-29 2016-10-26 Teva Pharma Forma de dosificacion unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolitico que comprende darunavir y ritonavir.
AU2015245217A1 (en) 2014-04-08 2016-10-13 Teva Pharmaceutical Industries Ltd. Unit dosage form comprising Emtricitabine, Tenofovir, Darunavir and Ritonavir
WO2018029561A1 (en) * 2016-08-08 2018-02-15 Hetero Labs Limited Anti-retroviral compositions
RU2659693C1 (ru) * 2017-06-30 2018-07-03 Общество с ограниченной ответственностью "Изварино Фарма" Фармацевтическая композиция, обладающая активностью против ВИЧ-инфекции
EP3569225A1 (en) 2018-05-18 2019-11-20 Pharmaceutical Oriented Services Ltd Solid dispersion containing ritonavir
CN114146061B (zh) * 2020-09-07 2023-06-30 歌礼生物科技（杭州）有限公司 包含固体分散体的蛋白酶抑制剂增效组合物及其制备方法
RU2760129C1 (ru) * 2020-12-04 2021-11-22 Общество с ограниченной ответственностью "АМЕДАРТ" Твёрдая фармацевтическая композиция для изготовления перорального антиретровирусного терапевтического средства

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141867A (en) * 1987-02-02 1992-08-25 E. I. Du Pont De Nemours And Company Nucleotide sequence encoding a human immunodeficiency virus antigen
AU4810490A (en) 1988-12-20 1990-07-10 Mawzones Developments Limited Focussing device for a microwave antenna
ATE135113T1 (de) 1988-12-20 1996-03-15 Clarity Technologies Inc Synthetische hiv ähnliche peptide, deren zusammensetzungen und verwendungen
US5539122A (en) 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
IL102092A (en) 1991-06-11 1996-11-14 Microgenesys Inc Use of recombinant VIH protein wrapped in VIH abduction drug and a pharmaceutical preparation containing the accumulated protein
DK0727419T3 (da) 1992-12-29 2002-06-10 Abbott Lab Mellemprodukter til fremstilling af forbindelser, som inhiberer retroviral protease
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
AU4828199A (en) 1998-06-23 2000-01-10 Board Of Trustees Of The University Of Illinois, The Multi-drug resistant retroviral protease inhibitors and associated methods
TWI286476B (en) 2001-12-12 2007-09-11 Tibotec Pharm Ltd Combination of cytochrome P450 dependent protease inhibitors
RU2275361C3 (ru) * 2002-11-20 2021-10-01 Джапан Тобакко Инк. Соединение 4-оксохинолина и его применение в качестве ингибитора вич интегразы
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
EP1765337B1 (en) 2004-07-08 2008-08-27 Tibotec Pharmaceuticals Ltd. Combination of tenofovir, ritonavir and tmc114
JP2008520672A (ja) * 2004-11-16 2008-06-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング チプラナビルとダルナビルの共投与によるｈｉｖ感染症の治療方法
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
RU2008128424A (ru) * 2005-12-14 2010-01-20 Сипла Лимитед (In) Фармацевтическая комбинация, включающая нуклеотидный и нуклеозидный ингибиторы обратной транскриптазы (такие как тенофовир и ламивудин) в различных частях дозы
GT200800303A (es) 2007-12-24 2009-09-18 Combinacion anti-retroviral

Also Published As

Publication number Publication date
CA2710605C (en) 2017-05-02
PE20091530A1 (es) 2009-09-25
RU2010131006A (ru) 2012-02-10
EP2505193A1 (en) 2012-10-03
EP2242482A2 (en) 2010-10-27
JO3376B1 (ar) 2019-03-13
CN101925350A (zh) 2010-12-22
HK1149905A1 (en) 2011-10-21
BRPI0819534A2 (pt) 2015-05-26
PE20140926A1 (es) 2014-08-06
US20110008429A1 (en) 2011-01-13
AU2008339633A1 (en) 2009-07-02
RU2531089C2 (ru) 2014-10-20
GT200800303A (es) 2009-09-18
AP2013007064A0 (en) 2013-08-31
CN103638032A (zh) 2014-03-19
RU2675831C2 (ru) 2018-12-25
DK2242482T3 (da) 2012-08-06
RU2014111723A (ru) 2015-10-10
ATE555778T1 (de) 2012-05-15
US9339470B2 (en) 2016-05-17
JP2011507940A (ja) 2011-03-10
ES2674730T3 (es) 2018-07-03
EP2242482B1 (en) 2012-05-02
EP2505193B1 (en) 2018-05-02
PA8809601A1 (es) 2009-07-23
CA2710605A1 (en) 2009-07-02
ES2385819T3 (es) 2012-08-01
CN101925350B (zh) 2014-04-30
AP2855A (en) 2014-02-28
WO2009081174A3 (en) 2009-08-27
JP2015007071A (ja) 2015-01-15
WO2009081174A2 (en) 2009-07-02
JO2814B1 (ar) 2014-09-15
AP2010005325A0 (en) 2010-08-31
ZA201004505B (en) 2013-05-29

Similar Documents

Publication Publication Date Title
MX2010007083A (es) Combinacion anti-retroviral.
LT2046298T (lt) Farmacinė vaisto forma, turinti farmaciniu požiūriu priimtiną soliubilizuojančią kompoziciją
IL184758A0 (en) New pharmaceutical compositions useful in the transmucosal administration of drugs
IL185390A (en) A solid dosage form
IL194460A0 (en) Deazapurine derivatives and pharmaceutical compositions containing the same
AU2008347158A8 (en) Oral pharmaceutical dosage forms
SI2343071T1 (sl) Farmacevtske odmerne oblike
EP2112925A4 (en) SOLID PHARMACEUTICAL DOSAGE FORMULATIONS
MX2012007375A (es) 3-ceto-n-propargil 1-aminoindano.
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
EP2045251A4 (en) COMPOUNDS WHICH CAN INCLUDE THE UBC13-UEV INTERACTIONS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS
MX2009011588A (es) Formas de dosificacion solidas que comprenden tadalafil.
ZA200810164B (en) Sustained release pharmaceutical dosage form containing phenylphrine
IL197574A0 (en) Pharmaceutical compositions
IL184114A0 (en) Use of diketodithiopiperazine antibiotics for the preparation of antiangiogenic pharmaceutical compositions
EP1862183A4 (en) PHARMACEUTICAL COMPOSITION WITH HEAVY WATER-SOLUBLE MEDICAMENT
IL178067A0 (en) Pharmaceutical dosage forms and compositions
MX343689B (es) Formulaciones combinadas de darunavir.
ZA200803152B (en) Oramucosal pharmaceutical dosage form
HK1112575A1 (en) Pharmaceutical composition in the form of a gastric-resident tablet containing an active principle
ZA200807348B (en) Dosage aerosols for the administration of pharmaceutical preparations
WO2010079433A3 (en) Pharmaceutical composition comprising melogliptin
EA201190282A1 (ru) Фармацевтическая композиция, содержащая тамсулозин
IL189827A0 (en) Pharmaceutical dosage forms and compositions comprising lecoztan
EP1948199A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF APTAMERS

Legal Events

Date Code Title Description
FG Grant or registration